Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. RARE
9. ACN
10. AZN

Go back to Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
(NASDAQ: ROIV) Delayed: 39.77 --0 (-0%)
Previous Close $39.77    52 Week High $ 
Open $39.77    52 Week Low $ 
Day High $39.77    P/E N/A 
Day Low $39.77    EPS $ 
Volume 7       

(NASDAQ: ROIVW) Delayed: 2.75 --0 (-0%)
Previous Close $2.75    52 Week High $ 
Open $25.55    52 Week Low $ 
Day High $2.75    P/E N/A 
Day Low $2.75    EPS $ 
Volume 555